PAK4 Inhibition Screening via E-Cadherin Expression Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development methods for pancreatic cancer and metastatic cancers lack effective treatments due to the lack of consideration of the metabolome, and pancreatic cancer has a high mortality rate with limited treatment options and rapid metastasis.
Innovation Solution
A method for screening PAK4 inhibition and E-cadherin expression inducers by measuring E-cadherin expression changes in cells overexpressing PAK4 after treatment with candidate substances, utilizing the novel mechanism of PAK4 regulating E-cadherin expression to develop targeted therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional drug development methods using in vitro cell experiments and animal experiments are used, then drug efficacy can be evaluated through traditional markers, but the actual drug efficacy as a substance close to the expression trait of the living body cannot be confirmed
Solution Approach 1:
The patent introduces metabolomics as an intermediary system between traditional in vitro cell experiments and actual living body expression traits. By measuring metabolite changes in cells overexpressing PAK4 before and after candidate substance treatment, the system bridges the gap between conventional evaluation methods and actual drug efficacy in living organisms, providing a more accurate prediction of therapeutic outcomes.
2Reliability
If PAK4 is inhibited to reduce cancer cell migration and invasion, then metastasis can be inhibited, but traditional treatment methods have not exceeded 12 months median survival
Solution Approach 1:
The patent applies preliminary action by screening and identifying candidate substances that inhibit PAK4 and induce E-cadherin expression before clinical application. Through in vitro cell experiments using cells overexpressing PAK4, the system pre-evaluates compounds' ability to restore E-cadherin expression and inhibit metastatic pathways, selecting the most promising candidates for further development to ultimately improve survival duration.
Solution Approach 2:
The patent utilizes parameter changes by measuring metabolite concentration changes as indicators of PAK4 inhibition efficacy and E-cadherin expression induction. By monitoring metabolic profile transformations in response to candidate substances, the system identifies compounds that effectively reverse the metastatic phenotype associated with PAK4 overexpression, thereby improving both metastasis inhibition and survival outcomes.
Data Source
Figure 1A~1B
Figure 1C
Figure 2A~2B
AI summary
The present specification pertains to a method for screening a p21-activated kinase (PAK4) inhibition and E-cadherin expression inducer using the novel mechanism of PAK4's regulation of E-cadherin expression and to a PAK4 inhibitor and E-Cadherin expression inducer, according to the method, useful for the prevention, treatment, or metastasis inhibition of cancer, particularly pancreatic cancer. Through the novel mechanism by which PAK4 regulates E-Cadherin expression, it is possible to develop targeted therapies for cancer or metastatic cancer effectively. Particularly provided can be first-in-class innovative new drugs in the field of pancreatic cancer or metastatic cancers derived from pancreatic cancer, where there is currently an unmet need due to the lack of effective treatments.